Tag Archives: IPO

Biotech IPOs smash record in H1, soaking up huge raises from the cash still parked on the sidelines. Will supply of buyers run out, like always?

The News: Last week the Nasdaq Biotech Index swooned 4% on Wednesday (July 27, 2018), only to rebound and halve that downdraft by Friday’s close (July 29, 2018). But despite… Read more »

Biotech IPO rain dance continues and not just in the USA. My take on where to place your bets.

It’s been said that biotechs are among the riskiest of initial public offerings due to the dualistic nature of their meds: they either succeed or they flop. There’s usually no… Read more »

Biotech IPO tsunami continues even as stocks sag following FDA chief’s drug-price rant.

The News: US Food and Drug Administration chief Scott Gottlieb on Thursday (May 3, 2018) questioned whether rebates that drugmakers provide to health insurers should remain protected by federal law,… Read more »

Healthcare IPOs sputter as uncertainty, anxiety cloud–everything; what is an issuer and investor to do?

Steve’s Take: After a perfectly miserable 2016, IPO issuers have been praying for a New England Patriots-style comeback. Bob Pisani at CNN says there are reasons to be optimistic. Leading… Read more »